Literature DB >> 15188160

Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study.

Jean Faivre1, Vincent Dancourt, Catherine Lejeune, Mohamed A Tazi, Joseph Lamour, Dominique Gerard, Frederic Dassonville, Claire Bonithon-Kopp.   

Abstract

BACKGROUND & AIMS: Several randomized population-based studies have shown that screening for colorectal cancer (CRC) by fecal occult blood tests (FOBTs) can reduce CRC mortality. The aim of this French population-based study was to assess whether a similar benefit could be obtained in countries characterized by high performances in the diagnosis and management of CRC.
METHODS: Small-sized geographic areas, including 91,199 individuals aged 45-74 years, were allocated to either FOBT screening or no screening. Six screening rounds were performed. The FOBT was performed without diet restriction and was sent to a central analysis center and processed without rehydration. Screening group participants who had a positive test result were offered a full colonoscopy. The entire population was followed up for 11 years after study entry.
RESULTS: Acceptability of the test was 52.8% at the first screening round and varied between 53.8% and 58.3% in the successive rounds. Positivity rates were 2.1% initially and 1.4% on average in the successive rounds. CRC mortality was significantly lower in the screening population compared with the control population (mortality ratio, 0.84; 95% confidence interval, 0.71-0.99). The reduction in CRC mortality was more pronounced in those who participated at least once (mortality ratio, 0.67; 95% confidence interval, 0.56-0.81).
CONCLUSIONS: Our findings, together with the results of other trials, suggest that biennial screening by FOBTs can reduce CRC mortality regardless of the quality of the health system and support attempts to introduce large-scale screening programs into the general population.

Entities:  

Mesh:

Year:  2004        PMID: 15188160     DOI: 10.1053/j.gastro.2004.02.018

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  99 in total

Review 1.  Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

Authors:  P Hewitson; P Glasziou; L Irwig; B Towler; E Watson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility.

Authors:  Richard Grieve; Marina Grishchenko; John Cairns
Journal:  Eur J Health Econ       Date:  2008-03-09

3.  The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening.

Authors:  Pauline Chauvin; Jean-Michel Josselin; Denis Heresbach
Journal:  Eur J Health Econ       Date:  2013-08-22

Review 4.  FIT testing: an overview.

Authors:  Lukejohn W Day; Taft Bhuket; James Allison
Journal:  Curr Gastroenterol Rep       Date:  2013-11

5.  A randomized controlled trial comparing water exchange and air insufflation during colonoscopy without sedation.

Authors:  Makoto Arai; Kenichiro Okimoto; Hideaki Ishigami; Takashi Taida; Arata Oyamada; Shoko Minemura; Keiko Saito; Masaru Tsuboi; Daisuke Maruoka; Tomoaki Matsumura; Tomoo Nakagawa; Tatsuro Katsuno; Kanae Mitsuhashi; Yuki Nakagawa; Kazuya Yamaguchi; Osamu Yokosuka
Journal:  Int J Colorectal Dis       Date:  2016-04-08       Impact factor: 2.571

Review 6.  Cancer Screening in the Elderly: A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening.

Authors:  Ashwin A Kotwal; Mara A Schonberg
Journal:  Cancer J       Date:  2017 Jul/Aug       Impact factor: 3.360

Review 7.  Stool Based Testing for Colorectal Cancer: an Overview of Available Evidence.

Authors:  Kevin M Rank; Aasma Shaukat
Journal:  Curr Gastroenterol Rep       Date:  2017-08

Review 8.  Colorectal cancer screening--optimizing current strategies and new directions.

Authors:  Ernst J Kuipers; Thomas Rösch; Michael Bretthauer
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

9.  Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

Authors:  Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Ann G Zauber; J Dik F Habbema; Ernst J Kuipers
Journal:  J Natl Cancer Inst       Date:  2009-09-24       Impact factor: 13.506

10.  Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands.

Authors:  Maaike J Denters; Marije Deutekom; Paul Fockens; Patrick M M Bossuyt; Evelien Dekker
Journal:  BMC Gastroenterol       Date:  2009-04-24       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.